10-11-07

Attorney's Docket No. 35784/209112 (5784-50)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl No.:

Caligiuri et al. 09/855,342

Confirmation No.: 8842

Filed:

May 14, 2001

Group Art Unit:

1642 Stephen L. Rawlings

For:

Examiner: METHODS OF THERAPY FOR CANCERS CHARACTERIZED BY

OVEREXPRESSION OF THE HER2 RECEPTOR PROTEIN

RECEIVED

Commissioner for Patents Washington, DC 20231

OCT 1 5 2002

TECH CENTER 1600/2900

RESPONSE TO REQUIREMENT FOR ELECTION OF SPECIES

This is in response to the Office Action dated September 10, 2002, in which the Examiner has required Applicants to elect a single disclosed species of anti-HER2 antibody for examination on its merits in the event that no generic claim is finally held to be allowable. Applicants hereby elect without traverse the anti-HER2 antibody 4D5 as the single disclosed species; claims 1-21 are readable thereon. Applicants expressly reserve the right to file a divisional application or take such other appropriate measures deemed necessary to protect the inventions encompassed by the nonelected species in the event that no generic claim is finally held to be allowable.

Should the Examiner have further questions or comments with respect to examination of this case, it is respectfully requested that the Examiner telephone the undersigned so that further examination of this application can be expedited.

It is not believed that extensions of time or fees for net addition of claims are required, beyond those, which may otherwise be provided for in documents accompanying this paper. However, in the event that additional extensions of time are necessary to allow consideration of this paper, such extensions are hereby petitioned under 37 CFR § 1.136(a), and any fee required therefore (including fees for net addition of claims) is hereby authorized to be charged to Deposit Account No. 16-0605.

Respectfully submitted,

Leslie T. Henry

Registration No. 45,714

CUSTOMER NO. 00826 ALSTON & BIRD LLP Bank of America Plaza

101 South Tryon Street, Suite 4000 Charlotte, NC 28280-4000 Tel Raleigh Office (919) 862-2200

Fax Raleigh Office (919) 862-2260

"Express Mail" mailing label number EL 868645805 US

Date of Deposit: October 10, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Commissioner For Patents.

Washington, DC 20231.